Pediatric transplantation · 2026
Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.
СтатьяМногоцентровое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pizzo H, Barbera A, Westreich K, Seifert M E, Mirocha J, Kirshner K, Puliyanda D
Аннотация
BACKGROUND: Alemtuzumab is an induction immunosuppressive agent effective in preventing hyperacute rejection; however, it can result in prolonged lymphocyte depletion. Here we assessed the dosing, tolerability, and outcomes with alemtuzumab induction via IV vs. SQ route in pediatric kidney transplantation.
METHODS: A multicenter analysis of 119 patients < 21 years old who received alemtuzumab induction immunosuppression. Total dose (mg) and dose by body weight (mg/kg) were assessed. Tolerability was defined by the development of leukopenia (WBC < 3.0 × 103/uL) or neutropenia (ANC < 1.5 × 103/uL). Outcomes in the first year post-transplant were defined by eGFR, hospitalizations, infections, development of de novo DSA, and rejection.
RESULTS: A total of 83 and 36 recipients received alemtuzumab IV and SQ, respectively. SQ group was slightly older, 14.0 y. (SD 5.5) vs. 11.9 y. (SD 6.1) (p = 0.07), and had more highly sensitized recipients, 14 (38.9%) vs. 10 (12.1%) (p = 0.002). Total dose and dose by weight were higher in the SQ group, 22.3 mg (SD 8.9) vs. 14.9 mg (SD 9.5), and 0.57 mg/kg (SD 0.21) vs. 0.36 mg/kg (SD 0.18 mg), respectively (p = 0.0001 and p < 0.0001). SQ group experienced more leukopenia and resultant medication dose reduction; however, there were no differences between the groups in eGFR, infections, hospitalizations, and rejection in the year following transplant.
CONCLUSION: Despite the higher dose of alemtuzumab and rates of leukopenia in the SQ group, there were no other differences in tolerability and outcomes compared to IV alemtuzumab. Overall, alemtuzumab is well tolerated during the first year post-transplant as an induction immunosuppression agent in the pediatric population.
METHODS: A multicenter analysis of 119 patients < 21 years old who received alemtuzumab induction immunosuppression. Total dose (mg) and dose by body weight (mg/kg) were assessed. Tolerability was defined by the development of leukopenia (WBC < 3.0 × 103/uL) or neutropenia (ANC < 1.5 × 103/uL). Outcomes in the first year post-transplant were defined by eGFR, hospitalizations, infections, development of de novo DSA, and rejection.
RESULTS: A total of 83 and 36 recipients received alemtuzumab IV and SQ, respectively. SQ group was slightly older, 14.0 y. (SD 5.5) vs. 11.9 y. (SD 6.1) (p = 0.07), and had more highly sensitized recipients, 14 (38.9%) vs. 10 (12.1%) (p = 0.002). Total dose and dose by weight were higher in the SQ group, 22.3 mg (SD 8.9) vs. 14.9 mg (SD 9.5), and 0.57 mg/kg (SD 0.21) vs. 0.36 mg/kg (SD 0.18 mg), respectively (p = 0.0001 and p < 0.0001). SQ group experienced more leukopenia and resultant medication dose reduction; however, there were no differences between the groups in eGFR, infections, hospitalizations, and rejection in the year following transplant.
CONCLUSION: Despite the higher dose of alemtuzumab and rates of leukopenia in the SQ group, there were no other differences in tolerability and outcomes compared to IV alemtuzumab. Overall, alemtuzumab is well tolerated during the first year post-transplant as an induction immunosuppression agent in the pediatric population.